https://www.yiliao.com/index.php?action=history&feed=atom&title=%E5%BC%A0%E5%8A%9B 2026-04-21T10:31:51Z 本wiki的该页面的版本历史 MediaWiki 1.35.1 https://www.yiliao.com/index.php?title=%E5%BC%A0%E5%8A%9B&diff=303499&oldid=prev 2017-12-05T15:50:32Z

<p></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="zh-Hans-CN"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2017年12月5日 (二) 15:50的版本</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l220" >第220行：</td> <td colspan="2" class="diff-lineno">第220行：</td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== 作为主要研究者的研究 ===</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== 作为主要研究者的研究 ===</div></td></tr> <tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>（Principle Investigator and/or Steering Committee <del class="diffchange diffchange-inline">member）</del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>（Principle Investigator and/or Steering Committee <ins class="diffchange diffchange-inline">member）：</ins></div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>1. A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib (BAY 43-9006) in chemonaïve patients with stage IIIB-IV non-small cell lung cancer (NSCLC) (NCT00558636). (Principle Investigator and Steering Committee member)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>1. A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib (BAY 43-9006) in chemonaïve patients with stage IIIB-IV non-small cell lung cancer (NSCLC) (NCT00558636). (Principle Investigator and Steering Committee member)</div></td></tr> </table>

凌潇 https://www.yiliao.com/index.php?title=%E5%BC%A0%E5%8A%9B&diff=303498&oldid=prev 2017-12-05T15:50:12Z

<p></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="zh-Hans-CN"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2017年12月5日 (二) 15:50的版本</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l278" >第278行：</td> <td colspan="2" class="diff-lineno">第278行：</td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>28. Dose Escalation and PK Study of  M2ES  in Subjects With Advanced Solid Tumors.( NCT01226030) (Principle Investigator)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>28. Dose Escalation and PK Study of  M2ES  in Subjects With Advanced Solid Tumors.( NCT01226030) (Principle Investigator)</div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>== 作为参加者的研究 ==</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">=</ins>== 作为参加者的研究 <ins class="diffchange diffchange-inline">=</ins>==</div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">'''</del>（Participant Trail）<del class="diffchange diffchange-inline">'''</del>:</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>（Participant Trail）:</div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>1. International, randomized, open-label, phase IIItrial of paclitaxel/carboplatin plus PF 3512676 Versuspaclitaxel/carboplatin aloneasfirst-linetreatment ofpatients with advanced non-small cell lung cancer.(NCT00254891)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>1. International, randomized, open-label, phase IIItrial of paclitaxel/carboplatin plus PF 3512676 Versuspaclitaxel/carboplatin aloneasfirst-linetreatment ofpatients with advanced non-small cell lung cancer.(NCT00254891)</div></td></tr> </table>

凌潇 https://www.yiliao.com/index.php?title=%E5%BC%A0%E5%8A%9B&diff=303497&oldid=prev 2017-12-05T15:49:36Z

<p></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="zh-Hans-CN"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2017年12月5日 (二) 15:49的版本</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l219" >第219行：</td> <td colspan="2" class="diff-lineno">第219行：</td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== 参加临床研究的情况 ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== 参加临床研究的情况 ==</div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">'''作为主要研究者（Principle </del>Investigator and/or Steering Committee <del class="diffchange diffchange-inline">member）的研究''':</del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">=== 作为主要研究者的研究 ===</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">（Principle </ins>Investigator and/or Steering Committee <ins class="diffchange diffchange-inline">member）</ins></div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>1. A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib (BAY 43-9006) in chemonaïve patients with stage IIIB-IV non-small cell lung cancer (NSCLC) (NCT00558636). (Principle Investigator and Steering Committee member)</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>1. A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib (BAY 43-9006) in chemonaïve patients with stage IIIB-IV non-small cell lung cancer (NSCLC) (NCT00558636). (Principle Investigator and Steering Committee member)</div></td></tr> </table>

凌潇 https://www.yiliao.com/index.php?title=%E5%BC%A0%E5%8A%9B&diff=303496&oldid=prev 2017-12-05T15:46:48Z

<p></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="zh-Hans-CN"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2017年12月5日 (二) 15:46的版本</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l52" >第52行：</td> <td colspan="2" class="diff-lineno">第52行：</td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>负责执笔撰写中国版《NCCN[[非小细胞肺癌]]临床指导原则》、《双磷酸盐治疗[[肺癌]]骨转移的专家共识》及《[[肿瘤]]相关贫血治疗专家共识》等多个临床共识，参与撰写《NCCN结肠/[[直肠癌]]临床指导原则》、《NCCN头颈癌临床指导原则》、《[[表皮生长因子]]受体抑制剂导致皮疹治疗的专家共识》。</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>负责执笔撰写中国版《NCCN[[非小细胞肺癌]]临床指导原则》、《双磷酸盐治疗[[肺癌]]骨转移的专家共识》及《[[肿瘤]]相关贫血治疗专家共识》等多个临床共识，参与撰写《NCCN结肠/[[直肠癌]]临床指导原则》、《NCCN头颈癌临床指导原则》、《[[表皮生长因子]]受体抑制剂导致皮疹治疗的专家共识》。</div></td></tr> <tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>==  </div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr> <tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>科研获奖 ==</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>== 科研获奖 ==</div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>1．《[[5-氟尿嘧啶]]/[[醛氢叶酸]]双周疗法治疗恶性肿瘤》    广东省科学技术研究成果三等奖，2006年度，排名第一</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>1．《[[5-氟尿嘧啶]]/[[醛氢叶酸]]双周疗法治疗恶性肿瘤》    广东省科学技术研究成果三等奖，2006年度，排名第一</div></td></tr> </table>

凌潇 https://www.yiliao.com/index.php?title=%E5%BC%A0%E5%8A%9B&diff=303495&oldid=prev 2017-12-05T15:41:04Z

<p></p> <a href="https://www.yiliao.com/index.php?title=%E5%BC%A0%E5%8A%9B&amp;diff=303495&amp;oldid=303494">显示更改</a>

凌潇 https://www.yiliao.com/index.php?title=%E5%BC%A0%E5%8A%9B&diff=303494&oldid=prev 2017-12-05T15:19:11Z

<p></p> <a href="https://www.yiliao.com/index.php?title=%E5%BC%A0%E5%8A%9B&amp;diff=303494&amp;oldid=303493">显示更改</a>

凌潇 https://www.yiliao.com/index.php?title=%E5%BC%A0%E5%8A%9B&diff=303493&oldid=prev 2017-12-04T15:18:06Z

<p></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="zh-Hans-CN"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2017年12月4日 (一) 15:18的版本</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l5" >第5行：</td> <td colspan="2" class="diff-lineno">第5行：</td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>'''性别'''：男</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>'''性别'''：男</div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>'''籍贯'''<del class="diffchange diffchange-inline">：中国</del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>'''籍贯'''<ins class="diffchange diffchange-inline">：</ins></div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>'''职务'''：中山大学[[肺癌]]研究所副所长</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>'''职务'''：中山大学[[肺癌]]研究所副所长</div></td></tr> </table>

凌潇 https://www.yiliao.com/index.php?title=%E5%BC%A0%E5%8A%9B&diff=302330&oldid=prev 2017-02-11T04:34:54Z

<p></p> <a href="https://www.yiliao.com/index.php?title=%E5%BC%A0%E5%8A%9B&amp;diff=302330&amp;oldid=302324">显示更改</a>

冰是睡着的水 https://www.yiliao.com/index.php?title=%E5%BC%A0%E5%8A%9B&diff=302324&oldid=prev 2017-02-10T16:39:14Z

<p>以“<a href="/%E6%96%87%E4%BB%B6:%E5%BC%A0%E5%8A%9B.jpg" title="文件:张力.jpg">thumb|200px|right|张力</a> &#039;&#039;&#039;姓名&#039;&#039;&#039;：张力 &#039;&#039;&#039;性别&#039;&#039;&#039;：男 &#039;&#039;&#039;籍贯&#039;&#039;&#039;：中国 &#039;&#039;&#039;职务&#039;&#039;&#039;：中山大学肺癌研究所副所长 ...”为内容创建页面</p> <a href="https://www.yiliao.com/index.php?title=%E5%BC%A0%E5%8A%9B&amp;diff=302324">显示更改</a>

冰是睡着的水